The Manufacturers Life Insurance Company raised its stake in shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 702.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,756 shares of the company’s stock after purchasing an additional 4,163 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Dova Pharmaceuticals were worth $137,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of DOVA. Wells Fargo & Company MN lifted its holdings in Dova Pharmaceuticals by 62.1% during the third quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock valued at $7,874,000 after purchasing an additional 124,287 shares in the last quarter. Pier Capital LLC lifted its stake in shares of Dova Pharmaceuticals by 118.5% in the third quarter. Pier Capital LLC now owns 116,715 shares of the company’s stock worth $2,834,000 after buying an additional 63,289 shares in the last quarter. Fosun International Ltd lifted its stake in shares of Dova Pharmaceuticals by 9.2% in the third quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock worth $17,239,000 after buying an additional 60,000 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Dova Pharmaceuticals by 2.8% in the third quarter. Perceptive Advisors LLC now owns 1,754,015 shares of the company’s stock worth $42,587,000 after buying an additional 47,516 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Dova Pharmaceuticals by 64.4% in the third quarter. Ameriprise Financial Inc. now owns 49,269 shares of the company’s stock worth $1,196,000 after buying an additional 19,300 shares in the last quarter. 26.05% of the stock is currently owned by institutional investors and hedge funds.
DOVA stock opened at $29.33 on Friday. Dova Pharmaceuticals Inc has a 52 week low of $16.98 and a 52 week high of $37.00.
Several equities analysts have recently weighed in on DOVA shares. BidaskClub downgraded shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Evercore ISI started coverage on shares of Dova Pharmaceuticals in a research note on Friday. They issued a “line” rating and a $29.00 price target on the stock. Finally, Jefferies Group raised their price target on shares of Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $32.00.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3296128/dova-pharmaceuticals-inc-dova-holdings-boosted-by-the-manufacturers-life-insurance-company.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.